aMoon Fund
aMoon is an Israeli healthcare and life sciences venture capital firm operating two funds (aMoon Velocity for early-stage and aMoon Growth for late-stage) plus an in-house value-creation platform (aMoon Alpha), serving healthtech and biotech founders globally with capital, talent, and corporate bridging.
- Company typePrivate
- Founded2016
- HeadquartersRa'anana, Israel
- Headcount11–50
- GTM typeB2B
- OfferingServices
What aMoon Fund does
aMoon is a private Israeli venture capital firm specializing in healthcare and life sciences, operating from Ra'anana, Israel with a secondary office in Boston. It invests across the healthcare stack — biopharma, medtech, diagnostics, and digital health — through two flagship vehicles: aMoon Velocity (early-stage) and aMoon Growth (late-stage). The firm was co-founded by Yair Schindel, MD, MBA, and is led by a partnership of scientists, physicians and operators (Tomer Berkovitz, PhD; Todd Sone, MBA; Moshic Mor, MBA; Yaron Daniely, PhD, MBA, who also heads aMoon Alpha; plus Partners Reut Shema, PhD and Roy Wiesner, Adv., MPA, and Portfolio Manager Patrick Rivers).
Layered on top of the two funds is aMoon Alpha, an in-house value-creation platform organized into three programmatic workstreams — Talent (global talent engine sourcing entrepreneurs and operators), Bridges (network connecting portfolio companies to Wall Street co-investors, large Biopharma/MedTech/Tech corporates, payers/providers, and research institutions), and Intelligence (proprietary research and trend analysis). aMoon also co-founded the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center and AWS, a 14-week program that has produced a founder pipeline from the Israeli tech-clinical ecosystem.
The business model is traditional venture capital economics — management fees on committed/limited-partner capital and carried interest on exits — with portfolio monetization demonstrated via NASDAQ-listed names (Adicet/ACET, Akoya Biosciences/AKYA, Ayala Pharmaceuticals/ADXS) and recent active rounds (MAGENTIQ EYE Series A led in July 2025; Connie Health $40M Series B participation in June 2026). Fund terms, AUM and check sizes are not publicly disclosed.
aMoon Fund firmographics
Firmographics- Name
- aMoon Fund
- Legal name
- aMoon Ventures Y.SH. Ltd
- Website
- https://amoon.fund
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- aMoon is an Israeli healthcare and life sciences venture capital firm operating two funds (aMoon Velocity for early-stage and aMoon Growth for late-stage) plus an in-house value-creation platform (aMoon Alpha), serving healthtech and biotech founders globally with capital, talent, and corporate bridging.
- Ownership category
- akta.pro rank
aMoon Fund industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
- akta.pro primary industry
- Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)
- akta.pro secondary industries
- Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), M&A Advisory (Buy-side/Sell-side) (BPAHADAC)
Keywords
Where aMoon Fund is headquartered
LocationHeadquarters
- HQ city
- Ra'anana
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
aMoon Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Venture Capital Fund Management & Investment Returns: aMoon operates two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthcare/healthtech companies pursuing disruptive solutions for high unmet medical needs. As a fund manager (aMoon Ventures Y.SH. Ltd), revenue is generated via traditional VC economics: management fees on committed/limited-partner capital and carried interest on investment returns, with portfolio exits delivered through IPOs (e.g., NASDAQ: ACET, AKYA, ADXS) and M&A.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | aMoon Velocity — early-stage fund; aMoon Growth — late-stage fund |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
aMoon Fund product offering
Product offeringCore offering
aMoon is a healthcare-focused venture capital firm that manages two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthtech, biopharma, medtech, and digital health companies pursuing disruptive solutions for high unmet medical needs. The firm layers an in-house value-creation platform, aMoon Alpha (Talent, Bridges, Intelligence), on top of the funds to support portfolio company execution, and co-runs the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center, and AWS.
Product overview
aMoon Fund is a healthcare-focused venture capital firm, not a software product company. Its offering is structured as a platform-plus-modules architecture comprising two core investment vehicles — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — that invest in healthcare companies pursuing disruptive solutions for high unmet medical needs. Layered on top of these funds is aMoon Alpha, an in-house value-creation platform with three programmatic modules (Talent, Bridges, Intelligence) that supports portfolio companies operationally. aMoon also co-founded the LEAP HealthTech Startup Accelerator together with 8200Bio, Rabin Medical Center, and AWS, which extends its offering into HealthTech venture formation.
Differentiator
Problem solved
Functional benefit
Brands
- aMoon Velocity: Early-stage investment fund focusing on early-stage healthcare companies pursuing disruptive solutions for high unmet medical needs.
- aMoon Growth
- aMoon Alpha
Products and services
- aMoon Velocity Early-stage venture fund that invests in healthcare companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. Targets pre-seed, seed, and Series A Israeli healthtech entrepreneurs leveraging breakthroughs at the convergence of tech and biology.
- aMoon Growth Late-stage venture fund that invests in healthcare companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. Provides growth capital, IPO readiness, and M&A support for more mature Israeli and global healthcare/healthtech companies ready to scale, IPO, or pursue strategic transactions.
- aMoon Alpha In-house value-creation team dedicated to strengthening portfolio companies' execution capabilities and unlocking additional value. Comprises three programs: Talent (global talent engine for entrepreneurs and managerial candidates), Bridges (connects portfolio companies with Biopharma, MedTech and Tech corporates, payers, and research institutions), and Intelligence (proprietary research and intelligence sources to support investment theses and market insights).
- LEAP HealthTech Startup Accelerator First-of-its-kind HealthTech accelerator co-created by aMoon with 8200Bio, Rabin Medical Center, and AWS. Brings together exceptional tech talent and practicing clinicians over a 14-week program of clinical tours, workshops, validation sessions, lectures, and panels to form the next wave of HealthTech startups in the Israeli ecosystem.
Quantifiable outcome
- Portfolio company Connie Health raised $40M Series B (aMoon as existing investor) bringing total funding to $85M; completed 10th acquisition (Clearlink's Medicare business)
- +4 more outcomes
Companies that use aMoon Fund
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles4 records
aMoon Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
aMoon Fund partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- 8200BiocoreCo-runner (with aMoon, Rabin Medical Center and AWS) of the inaugural LEAP cohort launched end of 2022 — a 14-week program to bring together tech talent and practicing clinicians to form the next wave of HealthTech startups. aMoon helped bring this program to life and supports identification and transition of exceptional tech talent into healthcare.
- Rabin Medical Center (Beilinson)coreCo-runner (with aMoon, 8200Bio and AWS) of the LEAP HealthTech program. Brings in clinical expertise from Beilinson's Innovation team and exposes founders to clinical realities through clinical tours, workshops and validation sessions.
- Amazon Web Services (AWS)coreCo-partner (with aMoon, 8200Bio and Rabin Medical Center) of the LEAP HealthTech program; contributes market expertise and go-to-market know-how to help founders validate and scale ventures.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
aMoon Fund competitors and assessment
Company assessmentDirect peers
- OrbiMed: One of the world's largest healthcare-dedicated investment firms with multi-billion AUM across venture, growth, credit, and royalties. Directly comparable to aMoon as a specialist healthcare/life-sciences VC, though at significantly larger scale.
- ARCH Venture Partners: U.S.-based, science-driven healthcare and technology VC managing large early- and late-stage funds. Closely comparable to aMoon in its tech-bio convergence thesis, founder-led model, and willingness to back early-stage moonshot science.
- RA Capital Management: Healthcare-focused investment firm with crossover, venture, and public-equity funds. Advisor Dr. Michael Sherman is a former RA Capital advisor, indicating direct relationship overlap. Comparable focus on biotech/healthtech investing across stages.
- HealthQuest Capital: Healthcare-dedicated growth-equity firm that led Connie Health's $40M Series B alongside aMoon. Comparable as a healthcare specialist that co-invests at growth stage with Israeli/global healthtech companies.
- Khosla Ventures: Large U.S. venture firm with deep healthcare/biotech practice. Existing co-investor alongside aMoon in Connie Health, and explicitly named as a participating investor in the Series B. Comparable in willingness to back early-stage moonshot science at the convergence of tech and biology.
- Pitango HealthTech: Israel's largest VC firm with a dedicated healthtech fund. Most direct geographic peer to aMoon within the Israeli healthtech ecosystem, competing for the same founder pool and co-invested in Connie Health.
- Flagship Pioneering: Biotech creation engine and investor behind Moderna. Comparable to aMoon in its tech-bio thesis, willingness to back moonshot science, and integrated value-creation platform; substantially larger AUM and a U.S. orientation.
- Section 32: Healthcare and tech investor founded by Bill Maris. Directly comparable in healthtech specialization, stage flexibility (seed to growth), and focus on tech-bio convergence — overlapping with aMoon's investment thesis.
Broad incumbents
- Bessemer Venture Partners (BVP): Large multi-stage venture firm with a substantial healthcare practice (Bessemer Venture Partners, formerly the BVP healthcare team). Comparable in healthtech investing breadth but operates as a broad generalist rather than a healthtech specialist.
- Deerfield Management: Healthcare-focused investment firm with venture, growth, and public-market strategies, plus operating services for portfolio companies. Comparable integrated platform approach (similar to aMoon Alpha) and willingness to support founders across stages.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
aMoon Fund social profiles
Digital presenceaMoon Fund compliance and trust
Trust signalCompliance1 record
aMoon Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
aMoon Fund leadership team
Management profileNumber of profiles
Profiles17 records
aMoon Fund funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
aMoon Fund M&A and investment
M&A and investmentM&A
Investments72 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about aMoon Fund
What does aMoon Fund do?
aMoon is a healthcare-focused venture capital firm that manages two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthtech, biopharma, medtech, and digital health companies pursuing disruptive solutions for high unmet medical needs. The firm layers an in-house value-creation platform, aMoon Alpha (Talent, Bridges, Intelligence), on top of the funds to support portfolio company execution, and co-runs the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center, and AWS.
Is aMoon Fund a public or private company?
aMoon Fund is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was aMoon Fund founded?
aMoon Fund was founded in 2016. It employs 11 to 50 people.
Where is aMoon Fund based?
aMoon Fund is headquartered in Ra'anana, Israel, in the Middle East region.
How does aMoon Fund make money?
One revenue line is on record: venture Capital Fund Management & Investment Returns.
Who are aMoon Fund's main competitors?
Direct peers on record are OrbiMed, ARCH Venture Partners, RA Capital Management, HealthQuest Capital, Khosla Ventures, Pitango HealthTech, Flagship Pioneering and Section 32. Broad incumbents are Bessemer Venture Partners (BVP) and Deerfield Management.
Does aMoon Fund have an API?
No public API is recorded for aMoon Fund.
What industry is aMoon Fund in?
aMoon Fund's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSAEAGAJ, Industry-Specialist / Sector-Focused M&A Advisory, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523940 and its SIC code is 6211.